溶栓
神经学
冲程(发动机)
医学
再灌注治疗
组织纤溶酶原激活剂
急性中风
心脏病学
内科学
重症监护医学
缺血
心肌梗塞
机械工程
精神科
工程类
作者
Alejandro A. Rabinstein
出处
期刊:Continuum
[Ovid Technologies (Wolters Kluwer)]
日期:2020-03-30
卷期号:26 (2): 268-286
被引量:219
标识
DOI:10.1212/con.0000000000000840
摘要
EDITOR’S NOTE The article “Update on Treatment of Acute Ischemic Stroke” by Dr Rabinstein was first published in the February 2017 Cerebrovascular Disease issue of Continuum: Lifelong Learning in Neurology as “Treatment of Acute Ischemic Stroke” and has been updated by Dr Rabinstein for this issue at the request of the Editor-in-Chief. ABSTRACT PURPOSE OF REVIEW This article provides an update on the state of the art of the treatment of acute ischemic stroke with particular emphasis on the indications for reperfusion therapy. RECENT FINDINGS In addition to the previously established indications for intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rtPA) within 4.5 hours of stroke symptom onset and endovascular therapy with mechanical thrombectomy for patients with large artery occlusion who can be treated within 6 hours of symptom onset, recent randomized controlled trials have now established new indications for emergency reperfusion in patients with wake-up stroke or delayed presentation (up to 24 hours from last known well in the case of mechanical thrombectomy). Identification of patients who may benefit from acute reperfusion therapy within this extended time window requires screening with perfusion brain imaging or, in the case of IV thrombolysis for wake-up strokes, emergency brain MRI. Collateral status and time to reperfusion remain the primary determinants of outcome. SUMMARY Timely successful reperfusion is the most effective treatment for patients with acute ischemic stroke. Recent evidence supports the expansion of the time window for reperfusion treatment in carefully selected patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI